Overall, the data from randomized placebo-controlled osteoarthritis trials have not shown any adverse effects on fasting blood glucose levels, glucose metabolism, or insulin sensitivity from oral GlcN, at any dose level. The gene discussed is INS; the disease is osteoarthritis.